-PTI The condition of government hospitals in Delhi drew a sharp criticism from Comptroller and Auditor General (CAG), which, in its report found several glaring shortcomings like unavailability of blood banks in five hospitals. The CAG today painted a sorry state of affairs at government hospitals in the national capital in its report for the fiscal year ending March 2012, which was tabled in Delhi Assembly. The government auditor said that scrutiny of...

-The Hindu Considering the knowledge of English as a mark of social advancement and that of the vernacular as backwardness disenfranchises significant sections of society In a village in Ghazipur district that borders Varanasi, there is a young man who teaches English and "personality development" to the sons and daughters of local shopkeepers, farmers and truck drivers. The classes are held from 6 to 8 in the morning and again in the...

-The Times of India KOLKATA: A 22-year-old post graduate student and leader of CPM's students' wing SFI, died of injuries sustained in police custody, prompting the Left Front to demand a judicial probe on Tuesday while chief minister Mamata Banerjee and her senior cabinet colleagues attended the IPL inauguration ceremony barely a few km away. Police claimed SFI state committee member Sudipto Gupta's death was an accident while the victim's kin alleged...

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...

-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...